Deutsche Bank Updates 6/21

Deutsche Bank made a number of updates in a research report published today. Biogen Idec BIIB had its rating upgraded from Hold to Buy. At the same time, Deutsche Bank raised its price target on the company's stock from $106 to $129. In the report, Deutsche Bank states, "Upgrading to Buy, $129 TP... Our TP is based on DCF (discount rate of 9% -- WACC based on a 2 year weekly beta of 0.84 (Bloomberg), risk free rate 3.0%, cost of debt 2.7%, equity risk premium 7.5%). Risks: (1) worse than expected BG-12 data in H2:11, (2) hemophilia trial failure and (3) erosion of Biogen's base business (Avonex/Tysabri)." On Monday, Biogen added 4.05% to its value to finish the day at $98.60. Its shares continued to climb higher in today's pre-market trading, however, rising 2.57% to $101.13. Bed Bath & Beyond BBBY had its rating maintained at Hold, and its price target reiterated at $55. The report states, "We estimate BBBY's long term EPS growth rate at 12% compared to the hardline average of 13%, mostly due to limited margin expansion from an already high level. Therefore, we base our $55 price target on 14x our 2012 forecast, implying a PEG of 110%, in line with the long term hardline average. We think the biggest risks are slowing consumer spending and exposure to housing markets." On Monday, BBBY added 1.15% to its value to close the day at $52.59. Its shares fell a bit in today's pre-market trading, however, sliding 0.02% to $52.58. Aon Corporation AON had its rating maintained at Buy and its price target reiterated at $63. The report states, "Aon has underperformed the group quarter-to-date, with investor concerns over brokerage margins in light of 1Q11 results, and with additional concerns over ability to maintain organic revenue growth in light of recent economic headlines regarding a slowing recovery. However, we believe that such fears are overblown, and expect that even modest improvements to top line and margins will provide a catalyst for the stock, 9% off its recent peak." On Monday, Aon added 0.38% to its value to end the day at $49.58. FedEx Corporation FDX had its rating maintained at Buy and its price target reiterated at $133. The report states, "FDX remains our top pick as we see a compelling risk/reward at current levels given the company's growth prospects, diversified product offering, network franchise, and secular growth of high tech and high value goods. FDX is Buy-rated with a $133 PT, which is based on 18x our CY2012 EPS estimate of $7.40. Risks include operating leverage, rising fuel prices, FedEx Freight's ongoing network restructuring, and the broader economy." On Monday, FedEx rose 0.59% to close the day at $87.50.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsAir Freight & LogisticsAONBed Bath & Beyondbiogen idecBiotechnologyConsumer DiscretionaryDeutsche BankfedexHealth CareHomefurnishing RetailIndustrials
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!